Paysign 경영진
경영진 기준 점검 3/4
Paysign CEO는 Mark Newcomer, Mar2006 에 임명되었습니다 의 임기는 20.17 년입니다. 총 연간 보상은 $2.75M, 38.1% 급여 및 61.9% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $62.32M 가치에 해당하는 회사 주식의 16.11% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 5.3 년과 8 년입니다.
핵심 정보
Mark Newcomer
최고경영자
US$2.8m
총 보수
| CEO 급여 비율 | 38.12% |
| CEO 재임 기간 | 20.2yrs |
| CEO 지분 보유율 | 16.1% |
| 경영진 평균 재임 기간 | 5.3yrs |
| 이사회 평균 재임 기간 | 8yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • May 20
PAYS: Higher Margin Guidance And Premium P/E Framework Will Drive Repricing
Analysts have nudged their fair value estimate for Paysign up from $12.00 to $12.75, citing updated assumptions around growth, margins, and future P/E that fed into the latest price target increase highlighted in recent Street research. Analyst Commentary Recent Street research highlights a more constructive tone around Paysign, with bullish analysts pointing to the refreshed fair value estimate and updated assumptions as key supports for their views.내러티브 업데이트 • Apr 30
PAYS: Higher Margin Outlook Will Support Repricing On Updated Profitability Assumptions
Analysts have raised their price target on Paysign by $1 to $12, citing updated assumptions around growth, profitability, discount rate and future P/E as the main drivers of this change. Analyst Commentary Bullish analysts are highlighting the recent price target move to US$12 as a sign of growing confidence in Paysign's outlook, with updated assumptions around growth, profitability, discount rate and future P/E at the core of their thesis.내러티브 업데이트 • Apr 12
PAYS: Higher Margin Outlook And Raised P/E Assumption Will Support Repricing
Analysts lifted their Paysign price target by $1 to reflect slightly higher modeled revenue growth, modestly stronger profit margins, and an adjusted future P/E assumption, all under broadly consistent fair value and discount rate inputs. Analyst Commentary Bullish analysts framing the recent price target move highlight that the updated P/E assumption and slightly higher modeled revenue and margins support a higher fair value range for Paysign, while keeping discount rate inputs broadly consistent.내러티브 업데이트 • Mar 28
PAYS: Higher Profit Margin Outlook Will Support More Constructive Share Repricing
The analyst price target for Paysign has increased from $9.50 to $12.00, with analysts citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E as key drivers of the change. Analyst Commentary Recent research points to a more constructive view on Paysign, with bullish analysts updating their models to reflect what they see as improved fair value assumptions and a more supportive outlook for key valuation inputs such as discount rate, revenue growth, profit margin and future P/E.분석 기사 • Feb 05
The Price Is Right For Paysign, Inc. (NASDAQ:PAYS) Even After Diving 27%
Paysign, Inc. ( NASDAQ:PAYS ) shareholders that were waiting for something to happen have been dealt a blow with a 27...분석 기사 • Nov 16
Paysign, Inc. Just Beat EPS By 100%: Here's What Analysts Think Will Happen Next
Paysign, Inc. ( NASDAQ:PAYS ) just released its quarterly report and things are looking bullish. The company beat...Seeking Alpha • Oct 01
Paysign: Gaining Traction In The Patient Affordability Space Into 2026 (Hold)
Summary Paysign posted strong Q2 2025 results, with 33% YoY revenue growth and robust Pharma segment momentum, driven by US tariffs and new client wins. PAYS is rated a hold, as the stock trades at fair value ($5.83), despite expected high demand for co-payment cards and expanded patient affordability programs. Pharma segment revenue surged 189% YoY, offsetting a 4.7% YoY decline in the core Plasma segment, which faces ongoing headwinds from transitioning centers. While PAYS benefits from industry tailwinds and guidance consistency, risks remain due to Plasma's weakness and Pharma revenues still lagging Plasma's overall contribution. Read the full article on Seeking Alpha분석 기사 • Aug 09
Paysign, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NasdaqCM:PAYS 1 Year Share Price vs Fair Value Explore Paysign's Fair Values from the Community and select yours One of...
내러티브 업데이트 • Aug 07
Digital Payment Solutions Will Expand Healthcare Access Further
Analysts maintain a positive outlook on Paysign due to ongoing growth in its Patient Affordability segment, confidence in its pharmaceutical pipeline, and scalable model, resulting in no change to the consensus price target, which remains at $9.10. Analyst Commentary Bullish analysts highlight a strong outlook for Paysign's Patient Affordability segment, especially within the pharmaceutical industry.분석 기사 • May 06
Paysign, Inc.'s (NASDAQ:PAYS) 28% Price Boost Is Out Of Tune With Earnings
Those holding Paysign, Inc. ( NASDAQ:PAYS ) shares would be relieved that the share price has rebounded 28% in the last...분석 기사 • Mar 04
Paysign, Inc.'s (NASDAQ:PAYS) Share Price Not Quite Adding Up
With a median price-to-earnings (or "P/E") ratio of close to 18x in the United States, you could be forgiven for...분석 기사 • Dec 27
Here's Why Paysign (NASDAQ:PAYS) Has Caught The Eye Of Investors
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Seeking Alpha • Nov 20
Paysign Is A Leader In Fintech Healthcare Payments With Durable Profitable Growth
Summary Paysign is a promising microcap payment processing company with a projected 42% annualized return, potentially reaching $19/share by 2030 from $3.30/share today. The company excels in two primary sectors: plasma payment processing and pharma patient affordability, both offering significant growth and high gross margins. PAYS's plasma business boasts a 40% market share with steady 10-15% annual growth, while the pharma segment is expected to surpass plasma with rapid expansion. Risks include increased competition, potential loss of key customers, and limited financial resources, but catalysts like market share gains and acquisition potential bolster the investment thesis. Read the full article on Seeking Alpha
새로운 내러티브 • Sep 26
Rapid Growth In Patient Affordability Market Fuels Optimism Despite Looming Margin Pressures
The expansion into the patient affordability segment and significant client growth, like AstraZeneca, indicates a promising area for revenue and earnings increases.분석 기사 • Sep 07
Do Paysign's (NASDAQ:PAYS) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...분석 기사 • Aug 02
Paysign, Inc. (NASDAQ:PAYS) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Paysign, Inc. ( NASDAQ:PAYS ) shareholders are probably feeling a little disappointed, since its shares fell 7.1% to...Seeking Alpha • Jun 30
Paysign: Expect Rapid Growth In Its Pharma Business
Summary Shares have risen sharply this year, reflecting solid business performance. Its pharma segment is experiencing exceptional growth and has a long runway for continued expansion. My valuation model indicates that shares have limited upside. Read the full article on Seeking Alpha분석 기사 • Apr 26
Paysign, Inc. (NASDAQ:PAYS) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Paysign, Inc. ( NASDAQ:PAYS ) shares have continued their recent momentum with a 30% gain in the last month alone. The...분석 기사 • Mar 29
Here's Why We Think PaySign (NASDAQ:PAYS) Is Well Worth Watching
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...분석 기사 • Jan 25
Revenues Tell The Story For PaySign, Inc. (NASDAQ:PAYS)
PaySign, Inc.'s ( NASDAQ:PAYS ) price-to-sales (or "P/S") ratio of 3.4x may not look like an appealing investment...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$10m |
| Dec 31 2025 | US$3m | US$1m | US$8m |
| Sep 30 2025 | n/a | n/a | US$8m |
| Jun 30 2025 | n/a | n/a | US$7m |
| Mar 31 2025 | n/a | n/a | US$6m |
| Dec 31 2024 | US$1m | US$1m | US$4m |
| Sep 30 2024 | n/a | n/a | US$8m |
| Jun 30 2024 | n/a | n/a | US$8m |
| Mar 31 2024 | n/a | n/a | US$7m |
| Dec 31 2023 | US$1m | US$950k | US$6m |
| Sep 30 2023 | n/a | n/a | US$2m |
| Jun 30 2023 | n/a | n/a | US$1m |
| Mar 31 2023 | n/a | n/a | US$1m |
| Dec 31 2022 | US$3m | US$950k | US$1m |
| Sep 30 2022 | n/a | n/a | US$420k |
| Jun 30 2022 | n/a | n/a | -US$703k |
| Mar 31 2022 | n/a | n/a | -US$1m |
| Dec 31 2021 | US$963k | US$950k | -US$3m |
| Sep 30 2021 | n/a | n/a | -US$7m |
| Jun 30 2021 | n/a | n/a | -US$13m |
| Mar 31 2021 | n/a | n/a | -US$12m |
| Dec 31 2020 | US$1m | US$950k | -US$9m |
| Sep 30 2020 | n/a | n/a | -US$3m |
| Jun 30 2020 | n/a | n/a | US$6m |
| Mar 31 2020 | n/a | n/a | US$8m |
| Dec 31 2019 | US$1m | US$883k | US$7m |
보상 대 시장: Mark의 총 보수(USD2.75M)는 US 시장에서 비슷한 규모 기업의 평균(USD2.64M) 수준입니다.
보상과 수익: Mark의 보상은 지난 1년 동안 20% 이상 증가했습니다.
CEO
Mark Newcomer (60 yo)
20.2yrs
재임 기간
US$2,754,265
보수
Mr. Mark R. Newcomer co-founded PaySign, Inc., (formerly known as 3Pea International, Inc.) and serves as its President from January 24, 2024, serves as Director since May 8, 2026 and has been its Chief Ex...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Co-Founder | 20.2yrs | US$2.75m | 16.11% $ 62.3m | |
| President of Patient Affordability | 5.9yrs | US$1.54m | 0.045% $ 172.6k | |
| Chief Innovation Officer | 1.2yrs | US$1.49m | 0% $ 0 | |
| CFO & Treasurer | 5.3yrs | US$697.56k | 0.69% $ 2.7m | |
| Chief Operating Officer | 2.3yrs | 데이터 없음 | 데이터 없음 | |
| Chief Technology Officer | 4.8yrs | 데이터 없음 | 데이터 없음 | |
| Chief Compliance Officer | 8.3yrs | 데이터 없음 | 데이터 없음 | |
| General Counsel | 7.6yrs | US$699.04k | 0.59% $ 2.3m | |
| Executive Vice President of Strategy & Corporate Development | 8.2yrs | 데이터 없음 | 데이터 없음 | |
| Vice President of Marketing | no data | 데이터 없음 | 데이터 없음 | |
| Executive VP of EFT Operations & Executive Director | 5.3yrs | 데이터 없음 | 1.5% $ 5.8m | |
| Chief Payments Officer & Director | 2.3yrs | 데이터 없음 | 0.34% $ 1.3m |
5.3yrs
평균 재임 기간
58yo
평균 나이
경험이 풍부한 관리: PAYS의 경영진은 노련하고 경험이 풍부합니다(평균 재임 5.3 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Co-Founder | no data | US$2.75m | 16.11% $ 62.3m | |
| Executive VP of EFT Operations & Executive Director | 7.5yrs | 데이터 없음 | 1.5% $ 5.8m | |
| Chief Payments Officer & Director | 3.8yrs | 데이터 없음 | 0.34% $ 1.3m | |
| Independent Chairman of the Board | 8yrs | US$164.20k | 0.23% $ 898.8k | |
| Independent Director | 3.4yrs | US$164.20k | 0.089% $ 346.0k | |
| Non-Executive Independent Director | 8yrs | US$164.20k | 0.45% $ 1.7m | |
| Member of Advisory Board | 11.6yrs | 데이터 없음 | 데이터 없음 | |
| Member of Advisory Board | 11.6yrs | 데이터 없음 | 데이터 없음 | |
| Non-Executive Independent Director | 8.2yrs | US$164.20k | 0.46% $ 1.8m |
8.0yrs
평균 재임 기간
68yo
평균 나이
경험이 풍부한 이사회: PAYS의 이사회는 경험이 있음으로 간주됩니다(평균 재임 8 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/27 23:56 |
| 종가 | 2026/05/27 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Paysign, Inc.는 6명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Gary Prestopino | Barrington Research Associates, Inc. |
| Austin Moldow | Canaccord Genuity |
| Peter Heckmann | D.A. Davidson & Co. |